HARASHIMA Hideyoshi 北海道大学, 薬学研究院, 教授 (00183567)
HYOUDOU Mamoru 北海道大学, 薬学研究院, 特任助教 (30548186)
NAGATSUGI Fumi 東北大学, 多元物質科学研究, 教授 (90208025)
SHINDO Mitsuru 九州大学, 先導物質化学研究所, 教授 (40226345)
NOMURA Masatoshi 九州大学, 医学部付属病院, 講師 (30315080)
|Budget Amount *help
¥207,090,000 (Direct Cost: ¥159,300,000、Indirect Cost: ¥47,790,000)
Fiscal Year 2013: ¥35,880,000 (Direct Cost: ¥27,600,000、Indirect Cost: ¥8,280,000)
Fiscal Year 2012: ¥35,880,000 (Direct Cost: ¥27,600,000、Indirect Cost: ¥8,280,000)
Fiscal Year 2011: ¥40,040,000 (Direct Cost: ¥30,800,000、Indirect Cost: ¥9,240,000)
Fiscal Year 2010: ¥43,160,000 (Direct Cost: ¥33,200,000、Indirect Cost: ¥9,960,000)
Fiscal Year 2009: ¥52,130,000 (Direct Cost: ¥40,100,000、Indirect Cost: ¥12,030,000)
Integrated research project for nucleic acids drug has been directed to nano-medicines that can target pathogenetic geneses. Achievements on chemical research for the artificial functional oligonucleotides, determination of the target genes, delivery system for selective targeting cells or tissues, and validation of the nano-medicine using model animals have been accumulates by mutual collaboration.
Newly-developed reactive oligonulceotides (ODN) are encapsulated in beta-MEND to target beta-cells, which are delivered into MIN6 cells of beta cell line, resulting in increase of insulin by releasing its native inhibition by miRNA-375 system. Bonkrekic acid, an apoptosis inhibitor, enhanced its activity by encapsulation in MITO-Porter, a mitochondria- targeting delivery system. siRNA targeting Drp1 gene was encapsulated in YSK-MEND (liver-targeting nano-envelope) for validate its effect for the model animal, and a potential as a new therapeutic approach has been suggested.